Skip to main content
Figure 1 | Breast Cancer Research

Figure 1

From: Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies

Figure 1

ROC curve analysis for progression of metastatic breast cancer in 26 patients. Nineteen of these patients were treated with trastuzumab (Herceptin) in combination with a taxane, one with trastuzumab (Herceptin) in combination with vinorelbine, and six with single-agent Herceptin without chemotherapy. The curve shows disease progression as a function of the percentage of change in the HER2/neu concentration from baseline to 2 to 4 weeks after the start of therapy. HER, human-epidermal-growth-factor receptor; ROC, receiver operating characteristic.

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us